SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022.
Vaccination coverage in the EU/EEA during autumn 2023 campaigns
Nearly 20 million people aged 60 years and above received COVID-19 vaccines during the autumn/winter campaign in the EU/EEA, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
How well does a flu vaccine work? DRIVE project evaluates performance
Despite challenging conditions posed by the COVID-19 outbreak, the DRIVE project successfully tested how well various brands of flu vaccines worked across five European countries and a range of age groups.
News
Policy & Recommendations
Data-informed decision-making: Driving life-course immunisation in National Immunisations Programs (NIPs)
CLCI, together with MEP Tomislav Sokol and the European Institute for Innovation through Health Data, has produced a report exploring ways of improving the use of data in national immunisation programme planning.
Public health action needed to mitigate the impact of respiratory pathogens for 2023-24 winter season in Europe
In an epidemiological update, the ECDC urges EU/EEA Member States to strengthen vaccination campaigns and prepare for the possible need to increase emergency department and ICU capacity
Evaluation of the effectiveness and impact of Nirsevimab in Galicia
The NIRSE-GAL study shows in real time the evolution of the coverage achieved by immunisation with Nirsevimab in children and compares RSV admissions in different population groups of children and adults in Galicia in Spain with previous years.
News
Policy & Recommendations
Study on the coherence, complementarity, and continued relevance of actions in the Council Recommendation on strengthened cooperation against vaccine-preventable diseases
Since 2018, the work of the European Commission on vaccination has been guided by the Council Recommendation on strengthened cooperation against vaccine-preventable diseases. The aim of this report is to support possible policy developments in the future.
First results in using new tools to tackle respiratory syncytial virus
Protecting infants from RSV with new tools: vaccines for pregnant women and use of monoclonal antibodies have been approved for use in the European Union to prevent RSV among young children. Are those tools working?
World Diabetes Day 2023: Why Influenza and Diabetes are important to consider jointly?
With the support of Sanofi, the Influenza Diabetes Community conducted a communications campaign to raise awareness of the impact of influenza on diabetes patients.
News
Policy & Recommendations
Flash Report: Third meeting of the Public Health Expert Group (PHEG)
Chaired by DG SANTE, EU Member States agreed on prioritising for 2024-2026: health promotion & prevention of non-communicable diseases; healthy longevity/lifelong prevention; vaccine-preventable diseases & vaccination; and long COVID, amongst others.
News
Scientific Papers
Article
Assessing the health burden of vaccine-preventable infections in European adults: challenges and opportunities translated into action
Accurate information on the health burden of vaccine-preventable infections (VPIs) is needed to support evidence-informed vaccine policy recommendations and programmes in Europe.
